Health News Releases

  • Today May 21
December 07, 2015 09:30
Samsung Bioepis' RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® - a biosimilar version of Remicade® (infliximab), also known as SB2 - for the tre
December 03, 2015 10:15
Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). The n
December 02, 2015 11:30
The Asian Acne Board and Galderma Join Forces to Improve Understanding and Management of Acne
The Asian Acne Board (AAB) and Galderma are inviting candidates to apply for a research grant of 10,000 USD to contribute to the improvement of best practices in the management of acne. The AAB res
December 01, 2015 11:20
Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs of Patients and Growing Importance of Generic Medicines Use in Japan
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that the two companies have entered into a definitive agreement to esta
December 01, 2015 10:10
Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of non-small cell lu
November 27, 2015 11:15
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran etexilate) in cases of emergency surger
November 24, 2015 10:25
Pfizer and Allergan to Combine
Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under wh
November 23, 2015 15:10
U.S. FDA Approves Takeda’s NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) (http://goo.gl/eX9kbP) today announced that the U.S. Food and Drug Administration (FDA) has approved NINLARO® (ixazomib) capsules, the first and only
November 23, 2015 10:15
Samsung Bioepis Receives Positive CHMP Opinion for the First Etanercept Biosimilar in the European Union
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Benepali® - a biosimilar ve
November 20, 2015 17:50
New Survey Showed GI Health and Anti-Aging Benefits of Morinaga's Probiotics Milk with BB536
Morinaga Milk Industry Co., Ltd. (www.morinagamilk.co.jp/english) (TOKYO:2264), Japanese leading dairy product company, today unveiled the results of a nationwide survey jointly conducted with Tokyo H
November 19, 2015 10:50
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Pfizer Inc. announced today that PROFILE 1029, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib), met its primary objective of significantly prolonging progression-fr
November 19, 2015 10:45
Merck and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designat
November 17, 2015 22:05
GORE® EXCLUDER® Iliac Branch Endoprosthesis Exceeds 1,000 Implants Worldwide
W. L. Gore & Associates, Inc. (Gore) (www.goremedical.com) today announced that the GORE® EXCLUDER® Iliac Branch Endoprosthesis has exceeded 1,000 implants worldwide. This milestone comes only two yea
November 17, 2015 22:00
Gore Achieves 40 Million Implants Sold Worldwide as it Celebrates 40 Years of Performance
W. L. Gore & Associates, Inc. (Gore) today announced in conjunction with its 40th anniversary, it has sold 40 million devices worldwide. The milestones come as the company showcases its latest innovat
November 17, 2015 16:40
Time is of the Essence for Millions Living with ‘Neglected’ Lung Disease: Your Time Campaign Calls for Earlier Action in COPD
Boehringer Ingelheim today announced the launch of the Your Time campaign - a worldwide call to raise public awareness of chronic obstructive pulmonary disease (COPD) and the importance of acting now.
November 17, 2015 14:15
India’s Leading Maternity and Birthing Care Hospital Group, Cloudnine, Adopts Masimo SET® Technology to Screen Infants for CCHD
Masimo (www.masimo.com) (NASDAQ: MASI) announced today that Cloudnine Hospital Group - a leader in providing premier quality healthcare to women and children in India - has upgraded system-wide to Mas
November 17, 2015 10:50
Pharco Pharmaceuticals Inc. Reports Ravidasvir Achieved 100% Cure Rate to Date When Combined with Sofosbuvir for HCV, Non-Cirrhotic, Genotype 4 Patients
Egypt’s leading drug manufacturer Pharco Pharmaceuticals, Inc. announced advanced results today from its Phase III clinical trial of the combination of ravidasvir with sofosbuvir for the treatment of
November 16, 2015 22:00
Replicor Discloses Continued Improvement of the Antiviral Response in Patients with HBV / HDV Co-Infection Receiving REP 2139-Ca Based Combination Therapy
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, disclosed upd
November 16, 2015 11:50
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim today announced the presentation of new analyses of OFEV® for the treatment of idiopathic pulmonary fibrosis (IPF) at the Pulmonary Fibrosis Foundation’s PFF Summit 2015 in Washin
November 16, 2015 10:00
Apira Science Inc. Expands iGrow Hair Growth System's Global Footprint Across Asia and Middle East
Apira Science, Inc. (www.apirascience.com) today announced that it has received clearance to sell and distribute the iGrow Hair Growth System (www.igrowlaser.com) in South Korea, Thailand, Singapore,
November 13, 2015 17:25
In New Study EMMA™ Capnograph Has Comparable Accuracy to Sidestream Capnography Against Gold-Standard Blood Gas Analysis
Masimo (www.masimo.com) (NASDAQ: MASI) announced today that in a new study that compared the end tidal carbon dioxide values (EtCO2) from both the Masimo EMMA capnograph and a conventional sidestream
November 12, 2015 14:25
Replicor Announces Publication of Its Pre-Clinical Data on the Therapeutic Effect of NAPs on Hepatitis B Virus Infection.
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the
November 12, 2015 13:35
Boehringer Ingelheim Will Invest 11 Billion Euros in Research and Development in the Next Five Years to Accelerate the Discovery of Next Generation Medical Breakthroughs
Boehringer Ingelheim is launching a new research and development (R&D) strategy and a five-year R&D investment programme. This new plan was announced today at its R&D press conference in Berlin. The c
November 11, 2015 10:55
Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab
Boehringer Ingelheim today announced it has completed enrollment for the pivotal Phase III trial (NCT02137226, https://goo.gl/gUgvqd) of BI695501, a biosimilar candidate to adalimumab (AbbVie’s Humira
November 11, 2015 10:40
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel dise
25 per page50 per page75 per page100 per page